- Kaposi Sarcoma, a rare cancer often linked with immunocompromised conditions such as HIV/AIDS, is witnessing rising prevalence, particularly in regions with high HIV incidence. Advancements in targeted therapies and immunomodulatory treatments are playing a crucial role in market expansion
- The market growth is largely fueled by the growing awareness, improved diagnostic capabilities, and increasing accessibility of antiretroviral therapy (ART), which prolongs patient survival and subsequently elevates the risk of Kaposi Sarcoma manifestation in HIV-positive individuals
- North America dominated the Kaposi Sarcoma market with the largest revenue share of 43.5% in 2024, driven by strong healthcare infrastructure, early diagnosis rates, and the presence of key pharmaceutical players. The U.S., in particular, leads the region with ongoing clinical trials and approvals for novel therapies
- Asia-Pacific is expected to be the fastest-growing region in the Kaposi sarcoma market during the forecast period, propelled by increasing awareness campaigns, improving healthcare access, and the rising burden of HIV/AIDS in countries such as India and Thailand
- The Epidemic (AIDS Associated) Kaposi sarcoma segment dominated the Kaposi Sarcoma market with a market share of 56.4% in 2024, primarily driven by the high incidence of HIV/AIDS, which significantly increases susceptibility to this form of the disease and necessitates targeted therapeutic interventions
